Cullen Frost Bankers Inc. Reduces Holdings in GSK plc (NYSE:GSK)

Cullen Frost Bankers Inc. reduced its stake in GSK plc (NYSE:GSK) by 22.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 319,703 shares of the pharmaceutical company’s stock after selling 94,436 shares during the period. Cullen Frost Bankers Inc.’s holdings in GSK were worth $10,812,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Indiana Trust & Investment Management Co increased its stake in shares of GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 500 shares during the period. Crews Bank & Trust purchased a new stake in GSK during the 4th quarter valued at $26,000. ST Germain D J Co. Inc. grew its holdings in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares during the last quarter. Sunbelt Securities Inc. increased its position in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the period. Finally, Sierra Ocean LLC bought a new position in shares of GSK during the fourth quarter valued at about $32,000. Institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of GSK stock opened at $39.30 on Friday. The business’s fifty day moving average is $35.35 and its 200 day moving average is $37.21. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The stock has a market cap of $81.46 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 1.12 and a beta of 0.58. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92.

GSK (NYSE:GSK) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.00%. GSK’s dividend payout ratio (DPR) is currently 98.74%.

Analysts Set New Price Targets

GSK has been the topic of several recent analyst reports. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.